Abstract:Background Type 1 diabetes mellitus (T1DM) is caused by immune cell-mediated β-cell dysfunction. In recent decades, N6-methyladenosine (m6A) has attracted widespread attention in the scientific research field because it plays vital roles in the pathogenesis of immunity-related diseases, including autoimmune diseases. However, neither the m6A modification profile nor the potential role it plays in T1DM pathogenesis has been investigated to date. Materials and Methods An m6A mRNA epitranscriptomic microarray analysis was performed to analyze m6A regulator expression patterns and m6A methylation patterns in immune cells of T1DM patients (n=6) and healthy individuals (n=6). A bioinformatics analysis was subsequently performed to explore the potential biological functions and signaling pathways underlying T1DM pathogenesis. Furthermore, mRNA expression and m6A methylation levels were subsequently verified by qRT–PCR and methylated RNA immunoprecipitation–qPCR (MeRIP–qPCR), respectively, in the T1DM and healthy groups (n=6 per group). Results Among the multiple m6A regulators, METTL3 and IGF2BP2 had significantly downregulated expression, and YTHDC1 and HNRNPA2B1 had significantly upregulated expression in the T1DM group relative to the healthy group. The microarray analysis revealed 4247 differentially methylated transcripts, including 932 hypermethylated and 3315 hypomethylated transcripts, and 4264 differentially expressed transcripts, including 1818 upregulated transcripts and 2446 downregulated transcripts in the T1DM group relative to the healthy group. An association analysis between methylation and gene expression demonstrated that the expression of 590 hypermethylated transcripts was upregulated, and that of 1890 hypomethylated transcripts was downregulated. Pearson correlation analysis showed significant correlations between the expression levels of differentially expressed m6A regulators and the methylation levels of differentially methylated transcripts and significant correlations between the expression levels of differentially expressed m6A regulators and that of differentially expressed transcripts. Moreover, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses demonstrated that differentially methylated transcripts were involved in pathways related to immunity, including some closely associated with T1DM. Conclusions Our study presents m6A regulator expression patterns and m6A methylation patterns of immune cells in T1DM, showing that the m6A mark and m6A regulators are promising targets for T1DM diagnosis and treatment.

Macrophage M1 regulatory diabetic nephropathy is mediated by m6A methylation modification of lncRNA expression

Abstract 4827: N6-Methyladenosine Modification of LINC00901 Promotes Pancreatic Cancer Progression

WTAP and METTL14 Regulate the M6a Modification of DKK3 in Renal Tubular Epithelial Cells of Diabetic Nephropathy

Mannose-binding Lectin Activates the Nuclear Factor-Κb and Renal Inflammation in the Progression of Diabetic Nephropathy.

Long non-coding RNA HCG18 promotes M1 macrophage polarization through regulating the miR-146a/TRAF6 axis, facilitating the progression of diabetic peripheral neuropathy

N6-methyladenosine methylation regulator RBM15 promotes the progression of diabetic nephropathy by regulating cell proliferation, inflammation, oxidative stress, and pyroptosis through activating the AGE-RAGE pathway

Comprehensive Analyses of Molecular Features, Prognostic Values, and Regulatory Functionalities of M6a-Modified Long Non-Coding RNAs in Lung Adenocarcinoma.

METTL14 derived from exosomes of M1 macrophages promotes high glucose-induced apoptosis, inflammation and oxidative stress in glomerular endothelial cells by mediating PAQR3 m6A modification

m6A mRNA methylation-directed myeloid cell activation controls progression of NAFLD and obesity

Sp1-Induced lncRNA Rmrp Promotes Mesangial Cell Proliferation and Fibrosis in Diabetic Nephropathy by Modulating the miR-1a-3p/JunD Pathway

N6-methyladenosine RNA methylation in diabetic kidney disease

LncRNA Dnmt3aos Regulates Dnmt3a Expression Leading to Aberrant DNA Methylation in Macrophage Polarization.

METTL3-mediated M6a Modification of TIMP2 Mrna Promotes Podocyte Injury in Diabetic Nephropathy

Long Noncoding RNA MEG3-205/Let-7a/MyD88 Axis Promotes Renal Inflammation and Fibrosis in Diabetic Nephropathy

Dysregulated m6A modification promotes lipogenesis and development of non-alcoholic fatty liver disease and hepatocellular carcinoma

New roles of N6-methyladenosine methylation system regulating the occurrence of non-alcoholic fatty liver disease with N6-methyladenosine-modified MYC

Dysregulation of Lncrnas GM5524 and GM15645 Involved in High‑glucose‑induced Podocyte Apoptosis and Autophagy in Diabetic Nephropathy.

The m6A methylation profiles of immune cells in type 1 diabetes mellitus

ERK Modulates Macrophage Polarization and Alters Exosome miRNA Expression in Diabetic Nephropathy.

METTL14 promotes glomerular endothelial cell injury and diabetic nephropathy via m6A modification of α-klotho

Characterization of lncRNA and mRNA profiles in rats with diabetic macroangiopathy